SCHEDULE: Morgan Stanley Reduces Stake in Perspective Therapeutics

Morgan Stanley has filed a Schedule 13G, reporting a beneficial ownership of 2.6% in Perspective Therapeutics, Inc. as of March 31, 2026, indicating a reduction in its holdings.

Summary

• Morgan Stanley has filed an amended Schedule 13G, reporting its beneficial ownership of Perspective Therapeutics, Inc. common stock.
• As of March 31, 2026, Morgan Stanley beneficially owns 2,959,296 shares, representing 2.6% of the class of securities.
• This filing indicates that Morgan Stanley has ceased to be the beneficial owner of more than five percent of the class of securities.
• The filing is made under Rule 13d-1(b) and Morgan Stanley is identified as a broker or dealer registered under section 15 of the Act.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While a reduction in ownership below 5% by a major institution can be noted, the filing itself is a routine disclosure and does not contain operational or financial performance data that would strongly influence sentiment.

Positives

• Morgan Stanley's filing confirms it is acting in the ordinary course of business, suggesting no intent to influence or control the company.
• The company is registered as a broker or dealer, indicating standard financial industry operations.

Negatives

• Morgan Stanley's beneficial ownership has fallen below the 5% threshold, which could be interpreted as a reduced conviction or strategic shift.

Risks

• The filing does not explicitly mention any specific risks related to the company's operations or financial health.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding future performance or strategy.

Management Comments

• "As of the date hereof, Morgan Stanley has ceased to be the beneficial owner of more than five percent of the class of securities."
• "In Accordance with the Securities and Exchange Commission Release No. 34-39538 (January 12, 1998) (the "Release"), this filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by certain operating units (collectively, the "MS Reporting Units") of Morgan Stanley and its subsidiaries and affiliates (collectively, "MS")."
• "This filing does not reflect securities, if any, beneficially owned by any operating units of MS whose ownership of securities is disaggregated from that of the MS Reporting Units in accordance with the Release."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and brokers to report holdings that cross the 5% ownership threshold. A reduction below this threshold by a significant entity like Morgan Stanley can sometimes signal a shift in institutional sentiment or a rebalancing of portfolios, though it is often a routine adjustment for large financial institutions.

Stakeholder Impact

• Shareholders: The reduction in Morgan Stanley's stake below 5% may be observed by shareholders, but without further context on the reasons for the reduction, its direct impact on share price is uncertain. It does not indicate a loss of confidence but rather a change in reporting status.
• Creditors: No direct impact on creditors is indicated by this filing.
• Employees: No direct impact on employees is indicated by this filing.
• Suppliers: No direct impact on suppliers is indicated by this filing.
• Customers: No direct impact on customers is indicated by this filing.

Next Steps

• Morgan Stanley will continue to monitor its holdings in Perspective Therapeutics, Inc. and file amendments to Schedule 13G as required by SEC regulations.

Key Dates

Keywords

Schedule 13G, Morgan Stanley, Perspective Therapeutics, Beneficial Ownership, SEC Filing, Common Stock, Broker-Dealer